Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Nucleoproteins – e.g. – chromatin – chromosomal proteins,...
Reexamination Certificate
1998-03-31
2001-05-15
Schwartzman, Robert A. (Department: 1635)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Nucleoproteins, e.g., chromatin, chromosomal proteins,...
C435S007100, C435S007230, C435S064000, C436S813000, C530S387100, C530S388100, C530S350000, C424S277100
Reexamination Certificate
active
06232443
ABSTRACT:
This invention was made with support from the National Kidney Fund of Western Pennsylvania and from the National Kidney Cancer Association.
BACKGROUND OF THE INVENTION
The present invention relates generally to renal nuclear matrix proteins, called “NMPs” here, and more specifically to novel nuclear matrix proteins of the kidney which are associated with cell-proliferative disorders.
U.S. Pat. Nos. 4,882,268 and 4,885,236, both issued to Fey and Penman, disclose certain NMPs and discuss their possible uses in identifying the origin of a tissue sample. In addition to identifying the origin of a tissue sample, the patents also discuss possible uses of NMPs to indicate certain disease states of a cell, such as viral infection, cancer, chromosomal defects or autoimmune disease. Specific NMPs discussed in the patents include those from human colon, lung, adrenal cortex and bladder cell lines.
The early diagnosis of renal cancer is central to the effective treatment of the disease. Currently, there are no methods available to easily and specifically identify the presence of renal cancer cells based on NMPs.
The nuclear matrix is the structural component of the nucleus that determines nuclear morphology, organizes the DNA in a three-dimensional fashion that is tissue specific, and has a central role in the regulation of a number of nuclear processes including the regulation of gene expression. The nuclear matrix has been demonstrated to play a central role in the regulation of important cellular processes such as DNA replication and transcription. Getzenberg,
J. Cell Biochem.
55: 22-31 (1994). The nuclear matrix is the framework or scaffolding of the nucleus and consists of the peripheral laminas and pore complexes, an internal ribonucleic protein network, and residual nucleoli. Berezney et al.,
Biochem. Biophys. Res. Comm.
60: 1410-17 (1974). The nuclear matrix consists of approximately 10% of the nuclear proteins and is virtually devoid of lipids, DNA and histones. Fey et al.,
Crit. Rev. Eukaryotic Gene Expression
1: 127-44 (1991).
A majority of the known NMPs are common to all cell types and physiologic states. A number of laboratories have identified NMPs which may be unique to certain cell types or states. Mitogenic stimulation and the induction of differentiation have been demonstrated to alter the composition of nuclear matrix proteins and structure. The nuclear matrix contains a number of associated proteins that have been demonstrated to be involved in transformation. Berezney first showed that the nuclear matrix is altered in transformation, examining hepatoma nuclear matrix proteins. Berezney et al.,
Cancer Res.
39: 3031-39 (1979). Fey and Penman demonstrated that tumor promoters induce a specific morphologic signature in the nuclear matrix-intermediate filament scaffold of kidney cells. Fey et al.,
Proc. Nat'l Acad. Sci. USA
81: 859-66 (1984). Fey and Penman went on to demonstrate that the pattern of NMPs differed between normal and tumorigenic cell lines. Fey et al., loc. cit. 85: 121-25 (1989). An antibody to a nuclear matrix protein, termed NM-200.4, was raised from the breast carcinoma cell line T-47D. Weidner et al.,
Am. J. Path.
138: 1293-98 (1991). This antibody reacts strongly with human breast carcinoma specimens as well as specimens from lung, thyroid, and ovarian cancers, but does not react with normal epithelial cells of similar origin, raising the possibility of the use of certain anti-NMP antibodies as diagnostic tools.
Exposure of canine kidney cells to various tumor promoters has also been found to alter the nuclear matrix-intermediate filament organization in these epithelial cells. Fey et al.,
Proc. Nat'l Acad. Sci. USA
81: 4409-4413 (1984).
It has been demonstrated with the Dunning rat model of prostate cancer that nuclear matrix protein composition is altered when comparing the normal dorsal prostate with the spontaneously arisen rat prostate adenocarcinomas. In U.S. Pat. No. 5,849,509, the entire contents of which are incorporated by reference herein, when human prostate samples were examined, nuclear matrix proteins were identified that (1) were present only in the normal prostate and were missing in both prostate cancer and benign prostatic hyperplasia (BPH) (normal pattern), (2) were found only in the prostate cancer cells and missing in the normal prostate and BPH (prostate cancer pattern), and (3) were found in both normal and BPH samples but were absent from prostate cancers.
In co-pending U.S. application Ser. No. 08/742,850 (now U.S. Pat. No. 5,866,535), the entire contents of which are incorporated by reference herein, NMPs are disclosed which are present only in normal bladder cells and are absent in bladder cancer cells. Also, the application discloses other NMPs that are found only in bladder cancer cells but are absent in normal bladder cells.
No nuclear matrix proteins have been isolated heretofore, however, that are linked specifically to renal cancer.
SUMMARY OF THE INVENTION
The present invention relates to nuclear matrix proteins that are able to differentiate cancerous renal cells from normal renal cells, polynucleotide sequences encoding them, and their methods of use. Five proteins, respectively designated RCCA-1, RCCA-2, RCCA-3, RCCA-4, and RCCA-5, have been discovered that are present in all cancerous renal cells that are not present in the normal renal cells, and one protein (referred to as RCNL-1) has been discovered that is unique to normal renal tissue. These proteins are useful for diagnosing and producing treatments for cell proliferative disorders of the kidney.
REFERENCES:
patent: 4882268 (1989-11-01), Penman et al.
patent: 4885236 (1989-12-01), Penman et al.
patent: 5273877 (1993-12-01), Fey et al.
patent: 5547928 (1996-08-01), Wu et al.
patent: 5824490 (1998-10-01), Coffey et al.
patent: 5849509 (1998-12-01), Coffey et al.
patent: 5866535 (1999-02-01), Getzenberg et al.
patent: WO87/03910 (1987-07-01), None
patent: WO93/09437 (1993-05-01), None
patent: WO94/00573 (1994-01-01), None
patent: WO94/18222 (1994-08-01), None
patent: WO95/16919 (1995-06-01), None
patent: WO97/16206 (1997-09-01), None
Miyanaga, N., et al., “Nuclear Matrix Proteins as a Urine Marker for Transitional Cell Carcinoma of the Bladder”. The Journal of Urology Supplement, vol. 153, No. 4 (XP-002068914) Apr. 23, 1995, p. 457A.
Merrifield, S., et al., “The Performance of the NMP22™ Test Kit: A Quantitative Enzyme Immuno-Assay for Bladder Cancer”,Tumor Biology,17 (suppl 1) (1996). (XP-002068915), p. 19.
Getzenberg, R., et al., “Bladder Cancer-associated Nuclear Matrix Proteins”,Cancer Researchvol. 56, No. 7, pp. 1690-1694, (1996). (XP002068894).
Konety, B.R., et al., “Identification of Nuclear Matrix Protein Alterations Associated with Renal Cell Carcinoma”,The Journal of Urology,vol. 159, No. 4, pp. 1359-1363 (1998). (XP002068895).
Eberharter A., et al., “Nuclear Matrix of the lower eukaryotePhysarum polycephalumand the mammalian epithelial LLC-PK1cell line—A comprehensive investigation of different preparation procedures”, vol. 212, No. 2 pp. 573-580 (1992). (XP02068893).
Keesee, S.K., et al., “Utilization of Nuclear Matrix Proteins for Cancer Diagnosis”,Critical Reviews in Eukaryotic Gene Expression,vol. 6, No. 2&3, pp. 189-214 (1996). (XP002069158).
Getzenberg, R. H., “Nuclear Matrix and the Regulation of Gene Expression: Tissue Specificity”,Journal of Cellular Biochemistry,vol. 55, pp. 22-31 (1994).
Getzenberg, R.H., et al., “Identification of Nuclear Matrix Proteins in the Cancer and Normal Rat Prostate”,Cancer Research,vol. 51, pp. 6514-6520 (1991).
Berezney, R., et al., “Identification of a Nuclear Protein Matrix”,Biochemical and Biophysical Research Communications,vol. 60, No. 4 (1974). p. 1410-1417.
Fey, E.G., et al., “The Nuclear Matrix: Defining Structural and Functional Roles”,Eukaryotic Gene Expression,pp. 127-143 (1991).
Fey, E.G., et al., “Tumor promoters induce a specific morphological signature in the nuclear matrix-intermediate filament scaffold of Madin-Darby canine kidney (MDCK) cell colonies”,Proc. Natl. A
Epps Janet
Foley & Lardner
Schwartzman Robert A.
University of Pittsburgh
LandOfFree
Renal nuclear matrix proteins, polynucleotide sequences... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Renal nuclear matrix proteins, polynucleotide sequences..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Renal nuclear matrix proteins, polynucleotide sequences... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2436992